{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:09:58Z","timestamp":1792130998367,"version":"4.4.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We established and characterized a bank of 138 CMVpp65 peptide-specific T-cell (CMVpp65CTLs) lines from healthy marrow transplant donors who consented to their use for treatment of individuals other than their transplant recipient. CMVpp65CTL lines included 131 containing predominantly CD8+ T cells and 7 CD4+ T cells. CD8+ CMVpp65CTLs were specific for 1 to 3 epitopes each presented by one of only 34 of the 148 class I alleles in the bank. Similarly, the 7 predominantly CD4+ CMVpp65CTL lines were each specific for epitopes presented by 14 of 40 HLA DR alleles in the bank. Although the number of HLA alleles presenting CMV epitopes is low, their prevalence is high, permitting selection of CMVpp65CTLs restricted by an HLA allele shared by transplant recipient and hematopoietic cell transplant donor for &amp;gt;90% of an ethnogeographically diverse population of hematopoietic cell transplant recipients. Within individuals, responses to CMVpp65 peptides presented by different HLA alleles are hierarchical. Furthermore, within groups, epitopes presented by HLA B*07:02 and HLA A*02:01 consistently elicit immunodominant CMVpp65CTLs, irrespective of other HLA alleles inherited. All dominant CMVpp65CTLs exhibited HLA-restricted cytotoxicity against epitope loaded targets and usually cleared CMV infections. However, immunodominant CMVpp65CTLs responding to epitopes presented by certain HLA B*35 alleles were ineffective in lysing CMV-infected cells in\u00a0vitro or controlling CMV infections post adoptive therapy. Analysis of the hierarchy of T-cell responses to CMVpp65, the HLA alleles presenting immunodominant CMVpp65 epitopes, and the responses they induce may lead to detailed algorithms for optimal choice of third-party CMVpp65CTLs for effective adoptive therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007005","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T16:55:36Z","timestamp":1653324936000},"page":"4859-4872","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4540-6904","authenticated-orcid":false,"given":"Aisha N.","family":"Hasan","sequence":"first","affiliation":[{"name":"1Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"2Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Doubrovina","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"2Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-9508","authenticated-orcid":false,"given":"Rosa","family":"Sottile","sequence":"additional","affiliation":[{"name":"3Immunology Program, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5728","authenticated-orcid":false,"given":"Susan","family":"Prockop","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"2Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Klatt","sequence":"additional","affiliation":[{"name":"4Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"6German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Heller","sequence":"additional","affiliation":[{"name":"7Department of Epidemiology and Biostatistics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamalai","family":"Selvakumar","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"2Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Barnett","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"2Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine C.","family":"Hsu","sequence":"additional","affiliation":[{"name":"3Immunology Program, and"},{"name":"8Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and"},{"name":"9Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"1Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"3Immunology Program, and"},{"name":"8Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and"},{"name":"9Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"issue":"4","key":"2022082518323293100_B1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1399-3062.2007.00235.x","article-title":"Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Almyroudis","year":"2007","journal-title":"Transpl Infect Dis."},{"issue":"7","key":"2022082518323293100_B2","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V83.7.1971.1971","article-title":"Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis","volume":"83","author":"Li","year":"1994","journal-title":"Blood."},{"issue":"4","key":"2022082518323293100_B3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood."},{"issue":"5","key":"2022082518323293100_B4","first-page":"813","article-title":"European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients","volume":"17","author":"Reusser","year":"1996","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"2022082518323293100_B5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med."},{"issue":"15","key":"2022082518323293100_B6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM199104113241501","article-title":"A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group","volume":"324","author":"Schmidt","year":"1991","journal-title":"N Engl J Med."},{"issue":"10","key":"2022082518323293100_B7","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study","volume":"88","author":"Boeckh","year":"1996","journal-title":"Blood."},{"issue":"1","key":"2022082518323293100_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med."},{"issue":"10","key":"2022082518323293100_B9","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","article-title":"Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings","volume":"94","author":"Tischer","year":"2015","journal-title":"Ann Hematol."},{"issue":"5","key":"2022082518323293100_B10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2022082518323293100_B11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/leu.2010.235","article-title":"Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3\/CD19 depleted grafts","volume":"25","author":"Federmann","year":"2011","journal-title":"Leukemia."},{"issue":"11","key":"2022082518323293100_B12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/bmt.2012.43","article-title":"Early evaluation of immune reconstitution following allogeneic CD3\/CD19-depleted grafts from alternative donors in childhood acute leukemia","volume":"47","author":"P\u00e9rez-Mart\u00ednez","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"2022082518323293100_B13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198207013070102","article-title":"Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients","volume":"307","author":"Quinnan","year":"1982","journal-title":"N Engl J Med."},{"issue":"5","key":"2022082518323293100_B14","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V78.5.1373.1373","article-title":"Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease","volume":"78","author":"Reusser","year":"1991","journal-title":"Blood."},{"issue":"11","key":"2022082518323293100_B15","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood."},{"issue":"20","key":"2022082518323293100_B16","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood."},{"issue":"9393","key":"2022082518323293100_B17","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet."},{"issue":"10","key":"2022082518323293100_B18","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood."},{"issue":"9","key":"2022082518323293100_B19","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"18","key":"2022082518323293100_B20","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood."},{"issue":"9331","key":"2022082518323293100_B21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet."},{"issue":"23","key":"2022082518323293100_B22","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood."},{"issue":"11","key":"2022082518323293100_B23","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood."},{"issue":"2","key":"2022082518323293100_B24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest."},{"key":"2022082518323293100_B25","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1182\/blood-2019-124904","article-title":"Long-term outcomes of subjects with Epstein-Barr-driven post-transplant lymphoproliferative disorder (EBV+PTLD) following solid organ (SOT) or allogeneic hematopoietic cell transplants (HCT) treated with tabelecleucel on an expanded access program","volume":"134","author":"Prockop","year":"2019","journal-title":"Blood."},{"issue":"26","key":"2022082518323293100_B26","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood."},{"issue":"23","key":"2022082518323293100_B27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.V126.23.623.623","article-title":"Third-party donor virus-specific T cells are efficacious in the treatment of refractory viral infection following allogeneic HSCT, but may persist post-infusion","volume":"126","author":"Withers","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2022082518323293100_B28","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/1521-4141(200006)30:6<1676::AID-IMMU1676>3.0.CO;2-V","article-title":"Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides","volume":"30","author":"Kern","year":"2000","journal-title":"Eur J Immunol."},{"issue":"7","key":"2022082518323293100_B29","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2003-05-1433","article-title":"Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy","volume":"105","author":"Trivedi","year":"2005","journal-title":"Blood."},{"issue":"7","key":"2022082518323293100_B30","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1172\/JCI119338","article-title":"Determination of antigen-specific memory\/effector CD4+\u00a0T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency","volume":"99","author":"Waldrop","year":"1997","journal-title":"J Clin Invest."},{"issue":"1","key":"2022082518323293100_B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"netMHCpan, a method for MHC class I binding prediction beyond humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics."},{"issue":"12","key":"2022082518323293100_B32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"issue":"Pt 11","key":"2022082518323293100_B33","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1099\/0022-1317-80-11-2867","article-title":"Modification of human cytomegalovirus tropism through propagation in\u00a0vitro is associated with changes in the viral genome","volume":"80","author":"Sinzger","year":"1999","journal-title":"J Gen Virol."},{"issue":"4","key":"2022082518323293100_B34","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1073\/pnas.87.4.1386","article-title":"Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells","volume":"87","author":"Simmons","year":"1990","journal-title":"Proc Natl Acad Sci USA."},{"issue":"20","key":"2022082518323293100_B35","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood."},{"issue":"9","key":"2022082518323293100_B36","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers","volume":"77","author":"Elkington","year":"2003","journal-title":"J Virol."},{"issue":"6","key":"2022082518323293100_B37","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood.V98.6.1872","article-title":"Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay","volume":"98","author":"Kuzushima","year":"2001","journal-title":"Blood."},{"issue":"1","key":"2022082518323293100_B38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/146532402317251518","article-title":"HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy","volume":"4","author":"Chen","year":"2002","journal-title":"Cytotherapy."},{"issue":"12","key":"2022082518323293100_B39","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022082518323293100_B40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol."},{"issue":"17","key":"2022082518323293100_B41","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/bloodadvances.2019000371","article-title":"\u201cMini\u201d bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood Adv."},{"issue":"12","key":"2022082518323293100_B42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"2022082518323293100_B43","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2003-03-0824","article-title":"Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles","volume":"103","author":"Kondo","year":"2004","journal-title":"Blood."},{"issue":"1","key":"2022082518323293100_B44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00018-004-4363-x","article-title":"Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire","volume":"62","author":"Nastke","year":"2005","journal-title":"Cell Mol Life Sci."},{"issue":"1","key":"2022082518323293100_B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-9-1","article-title":"HLA class I supertypes: a revised and updated classification","volume":"9","author":"Sidney","year":"2008","journal-title":"BMC Immunol."},{"issue":"7","key":"2022082518323293100_B46","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.172.7.4314","article-title":"Identifiying human MHC supertypes using bioinformatic methods","volume":"172","author":"Doytchinova","year":"2004","journal-title":"J Immunol."},{"issue":"6533","key":"2022082518323293100_B47","doi-asserted-by":"crossref","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science."},{"issue":"4","key":"2022082518323293100_B48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0198-8859(03)00028-4","article-title":"Relative dominance of HLA-B*07 restricted CD8+\u00a0T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles","volume":"64","author":"Lacey","year":"2003","journal-title":"Hum Immunol."},{"issue":"5","key":"2022082518323293100_B49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10875-005-5372-8","article-title":"T cell control of primary and latent cytomegalovirus infections in healthy subjects","volume":"25","author":"Lidehall","year":"2005","journal-title":"J Clin Immunol."},{"issue":"12","key":"2022082518323293100_B50","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1002\/eji.201343597","article-title":"Co-expression of HLA-B7 and HLA-B27 alleles is associated with B7-restricted immunodominant responses following influenza infection","volume":"43","author":"Akram","year":"2013","journal-title":"Eur J Immunol."},{"issue":"7018","key":"2022082518323293100_B51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature03113","article-title":"Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA","volume":"432","author":"Kiepiela","year":"2004","journal-title":"Nature."},{"issue":"6665","key":"2022082518323293100_B52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/34929","article-title":"HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes","volume":"391","author":"Collins","year":"1998","journal-title":"Nature."},{"issue":"23","key":"2022082518323293100_B53","doi-asserted-by":"crossref","first-page":"12643","DOI":"10.1128\/JVI.01381-12","article-title":"Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope","volume":"86","author":"Matthews","year":"2012","journal-title":"J Virol."},{"issue":"9","key":"2022082518323293100_B54","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/JVI.02892-15","article-title":"Immunodominant dengue virus-specific CD8+\u00a0T cell responses are associated with a memory PD-1+ phenotype","volume":"90","author":"de Alwis","year":"2016","journal-title":"J Virol."},{"issue":"1","key":"2022082518323293100_B55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1074-7613(00)80161-2","article-title":"Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses","volume":"12","author":"Chen","year":"2000","journal-title":"Immunity."},{"issue":"2","key":"2022082518323293100_B56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2004.06.015","article-title":"Immunodominance in TCD8+\u00a0responses to viruses: cell biology, cellular immunology, and mathematical models","volume":"21","author":"Yewdell","year":"2004","journal-title":"Immunity."},{"issue":"9","key":"2022082518323293100_B57","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.175.9.6123","article-title":"Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses","volume":"175","author":"Trautmann","year":"2005","journal-title":"J Immunol."},{"issue":"16","key":"2022082518323293100_B58","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood-2012-03-420182","article-title":"Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+\u00a0T cells","volume":"120","author":"Smith","year":"2012","journal-title":"Blood."},{"issue":"7","key":"2022082518323293100_B59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nri2575","article-title":"MHC class I antigen presentation: learning from viral evasion strategies","volume":"9","author":"Hansen","year":"2009","journal-title":"Nat Rev Immunol."},{"issue":"10","key":"2022082518323293100_B60","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/ni.2097","article-title":"Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1","volume":"12","author":"Kim","year":"2011","journal-title":"Nat Immunol."},{"issue":"8","key":"2022082518323293100_B61","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1128\/jvi.69.8.4830-4841.1995","article-title":"Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains","volume":"69","author":"Jones","year":"1995","journal-title":"J Virol."},{"issue":"12","key":"2022082518323293100_B62","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.4049\/jimmunol.171.12.6757","article-title":"Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation","volume":"171","author":"Barel","year":"2003","journal-title":"J Immunol."},{"issue":"12","key":"2022082518323293100_B63","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.4049\/jimmunol.1302281","article-title":"CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity","volume":"192","author":"Ameres","year":"2014","journal-title":"J Immunol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4859\/1917926\/advancesadv2022007005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4859\/1917926\/advancesadv2022007005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T14:33:23Z","timestamp":1661438003000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/16\/4859\/485323\/Dominant-epitopes-presented-by-prevalent-HLA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":63,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,8,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007005","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}